Celgene's experimental cell therapy JCAR017, or liso-cel, could prove competitive in lymphoma with already on-market treatments from Gilead and Novartis, suggest updated clinical results presented Sunday at the annual meeting of the American Society of Clinical Oncology.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,